Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffany Escobar

Nurse Practitioner, Primary Care Cincinnati, OH Nurse Practitioner

NPI 1053821686 CMS profile 11188982

8240 Northcreek Dr, Cincinnati, OH 45236

Open in the dashboard

General payments

$3,266

78 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Escobar of Cincinnati, OH is reported in the CMS Open Payments database as having received $3,266 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184 7
2024 General $1,687 22
2023 General $370 5
2022 General $298 9
2021 General $727 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Escobar
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Tiffany Escobar were reported at $184. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Tiffany Escobar Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $727 $137 $39–$445 $132
2022 $298 $139 $44–$421 $149
2023 $370 $163 $53–$481 $160
2024 $1,687 $176 $54–$511 $164
2025 $184 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,535 17 payments
  2. Abbott Laboratories $438 9 payments
  3. Medtronic, Inc. $216 5 payments
  4. Averitas Pharma Inc. $152 3 payments
  5. AbbVie, Inc. $139 7 payments
  6. Amgen Inc. $122 5 payments
  7. Biohaven Pharmaceuticals, Inc. $80 3 payments
  8. Allergan Inc. $74 4 payments
  9. Lilly USA, LLC $59 4 payments
  10. Curonix LLC $54 2 payments
  11. Other $397 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,383 73 payments
  2. Travel and Lodging $883 5 payments
Products named General payments · program years 2021–2025
  1. Intracept $1,153 9 payments
  2. PROCLAIM $252 6 payments
  3. Qutenza $184 4 payments
  4. INTELLIS ADAPTIVESTIM $179 3 payments
  5. ETERNA $170 2 payments
  6. Superion Indirect Decompression System $150 1 payment
  7. UBRELVY $117 6 payments
  8. AIMOVIG $117 5 payments
  9. NURTEC ODT $80 3 payments
  10. EMGALITY $59 4 payments
  11. Other $777 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,321

Median for Nurse Practitioner: 389

Drug cost

$64,905

Median for Nurse Practitioner: $21,885

Branded share of claims

37.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 20 $13,823
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 420 $9,930
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 405 $7,843
Belbuca Buprenorphine Hcl Brand 17 $7,300
Buprenorphine Generic 34 $5,474
Pregabalin Generic 184 $5,137
Gabapentin Generic 394 $4,563
Tramadol Hcl Generic 204 $1,756
Lidocaine Generic 14 $1,589
Cyclobenzaprine Hcl Generic 45 $1,189

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$43,511

Of which drugs: $1,312

Medicare patients

168

Average age 74

Services billed

1,055

108 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Ischemic heart disease 35%
Diabetes 27%
Chronic kidney disease 26%
Osteoporosis 24%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 68 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $152
$152 — —
UBRELVY
  • AbbVie, Inc. $15
$15 — —
QULIPTA
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record